Literature DB >> 19027721

TLR4-dependent and -independent regulation of hepatic cytochrome P450 in mice with chemically induced inflammatory bowel disease.

Madhusudana R Chaluvadi1, Beatrice A Nyagode, Ryan D Kinloch, Edward T Morgan.   

Abstract

The transcription and protein expression of many cytochrome P450 (P450) genes are down-regulated in animal models of inflammation and infection. We determined previously that hepatic P450 mRNAs are selectively regulated in a mouse model of enteropathogenic bacterial infection, and that this regulation was not dependent on the lipopolysaccharide (LPS) receptor protein toll-like receptor 4 (TLR4). In the dextran sulfate sodium (DSS) model of chemically induced inflammatory bowel disease (IBD), the reduction in activities of several hepatic P450 enzymes were concluded to be partially dependent on LPS from commensal bacteria [Masubuchi Y, Horie T. Endotoxin-mediated disturbance of hepatic cytochrome P450 function and development of endotoxin tolerance in the rat model of dextran sulfate sodium-induced experimental colitis. Drug Metab Dispos 2004;32:437-441]. In the present study, we sought to determine whether colitis induced by LPS regulates hepatic P450 mRNA and protein expression similarly to infectious colitis, and to determine the role of TLR4 in the response to DSS colitis. The role of LPS in the response to DSS was further examined by comparison with the effects of injected LPS. We demonstrate that administration of DSS results in the down-regulation of multiple P450 enzymes in mouse liver. However, there are discernable differences in the pattern of P450 expression in the two models. Some effects of DSS-induced colitis are TLR4-dependent, and others are not. In contrast, the effects of injected LPS on hepatic P450 mRNA expression are entirely TLR4-dependent. Thus, our results indicate that the pattern of hepatic P450 expression, and the mechanism of regulation, during inflammation of the bowel depend on the etiology of the disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19027721      PMCID: PMC2932663          DOI: 10.1016/j.bcp.2008.10.029

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  23 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

3.  Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure.

Authors:  Reginald F Frye; Virginia M Schneider; Carole S Frye; Arthur M Feldman
Journal:  J Card Fail       Date:  2002-10       Impact factor: 5.712

Review 4.  Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance.

Authors:  L Caradonna; L Amati; T Magrone; N M Pellegrino; E Jirillo; D Caccavo
Journal:  J Endotoxin Res       Date:  2000

5.  Disturbed bile secretion and cytochrome P450 function during the acute state of experimental colitis in rats.

Authors:  H Weidenbach; S Leiz; A K Nussler; N Dikopoulos; M Bachem; K Buttenschoen; M Reinshagen; H G Beger; G Adler; R M Schmid
Journal:  J Hepatol       Date:  2000-05       Impact factor: 25.083

6.  Characterization of CYP4A induction in rat liver by inflammatory stimuli: dependence on sex, strain, and inflammation-evoked hypophagia.

Authors:  S R Mitchell; M B Sewer; S S Kardar; E T Morgan
Journal:  Drug Metab Dispos       Date:  2001-01       Impact factor: 3.922

7.  Properties of electrophoretically homogeneous phenobarbital-inducible and beta-naphthoflavone-inducible forms of liver microsomal cytochrome P-450.

Authors:  D A Haugen; M J Coon
Journal:  J Biol Chem       Date:  1976-12-25       Impact factor: 5.157

Review 8.  Inflammatory bowel disease: Crohn's disease and the success of NODern genetics.

Authors:  Bill Newman; Katherine Siminovitch
Journal:  Clin Invest Med       Date:  2003-12       Impact factor: 0.825

9.  Endotoxin-mediated disturbance of hepatic cytochrome P450 function and development of endotoxin tolerance in the rat model of dextran sulfate sodium-induced experimental colitis.

Authors:  Yasuhiro Masubuchi; Toshiharu Horie
Journal:  Drug Metab Dispos       Date:  2004-04       Impact factor: 3.922

10.  MD-2: the Toll 'gatekeeper' in endotoxin signalling.

Authors:  Monique Gangloff; Nicholas J Gay
Journal:  Trends Biochem Sci       Date:  2004-06       Impact factor: 13.807

View more
  13 in total

Review 1.  Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics.

Authors:  E T Morgan
Journal:  Clin Pharmacol Ther       Date:  2009-02-11       Impact factor: 6.875

2.  Selective role for tumor necrosis factor-α, but not interleukin-1 or Kupffer cells, in down-regulation of CYP3A11 and CYP3A25 in livers of mice infected with a noninvasive intestinal pathogen.

Authors:  Ryan D Kinloch; Choon-Myung Lee; Nico van Rooijen; Edward T Morgan
Journal:  Biochem Pharmacol       Date:  2011-05-06       Impact factor: 5.858

3.  Sesamin Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Inhibition of TLR4 Signaling Pathways.

Authors:  Li Qiang; Jiang Yuan; Jiang Shouyin; Li Yulin; Jiang Libing; Wang Jian-An
Journal:  Inflammation       Date:  2016-02       Impact factor: 4.092

4.  Mice Fed a High-Fat Diet Supplemented with Resistant Starch Display Marked Shifts in the Liver Metabolome Concurrent with Altered Gut Bacteria.

Authors:  Dorothy A Kieffer; Brian D Piccolo; Maria L Marco; Eun Bae Kim; Michael L Goodson; Michael J Keenan; Tamara N Dunn; Knud Erik Bach Knudsen; Roy J Martin; Sean H Adams
Journal:  J Nutr       Date:  2016-11-02       Impact factor: 4.798

5.  Modulation of hepatic cytochrome P450s by Citrobacter rodentium infection in interleukin-6- and interferon-{gamma}-null mice.

Authors:  Beatrice A Nyagode; Choon-Myung Lee; Edward T Morgan
Journal:  J Pharmacol Exp Ther       Date:  2010-08-18       Impact factor: 4.030

6.  Selective modulation of hepatic cytochrome P450 and flavin monooxygenase 3 expression during citrobacter rodentium infection in severe combined immune-deficient mice.

Authors:  Beatrice A Nyagode; William J Watkins; Ryan D Kinloch; Edward T Morgan
Journal:  Drug Metab Dispos       Date:  2012-06-27       Impact factor: 3.922

7.  Hepatic flavin-containing monooxygenase gene regulation in different mouse inflammation models.

Authors:  Jun Zhang; Madhusudana R Chaluvadi; Rob Reddy; Meike S Motika; Terrilyn A Richardson; John R Cashman; Edward T Morgan
Journal:  Drug Metab Dispos       Date:  2008-12-16       Impact factor: 3.922

Review 8.  Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody.

Authors:  Abhijit Chakraborty; Stacey Tannenbaum; Christiane Rordorf; Philip J Lowe; David Floch; Hermann Gram; Sandip Roy
Journal:  Clin Pharmacokinet       Date:  2012-06-01       Impact factor: 6.447

Review 9.  The regulation of drug-metabolizing enzymes and membrane transporters by inflammation: Evidences in inflammatory diseases and age-related disorders.

Authors:  Kuo-Chen Wu; Chun-Jung Lin
Journal:  J Food Drug Anal       Date:  2018-12-04       Impact factor: 6.157

Review 10.  Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment.

Authors:  Françoise Stanke-Labesque; Elodie Gautier-Veyret; Stephanie Chhun; Romain Guilhaumou
Journal:  Pharmacol Ther       Date:  2020-07-11       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.